PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 19, 2025 09:33 ET This week's video covers several intriguing topics: a merger of two pharma companies with a troubled past to create a global, diversified pharmaceuticals leader; a novel therapy in the works that could change the treatment landscape of Hunter syndrome, if approved; and a partnership to unlock Petrelintide’s potential for obesity treatment. Additionally, we explore the CDC's investigation into a potential link between vaccines and autism, amid the growing number of autism diagnoses.
A new study from Cedars-Sinai found that many more people than usual suffered from heart attacks, lung problems, and general illnesses in the three months after the January 2025 wildfires in Los Angeles. Notably, these health problems showed up within 90 days of the fires starting, suggesting that the...
A recent study by the American Psychological Association suggests that swearing can help people perform better during physically demanding tasks by letting them push harder. Researchers noted that this happens because swearing reduces mental and social restraints that usually hold people back. "In...
Biotest AG, Friday announced that its parent company Grifols, S.A. (GRFS) has received approval from the U.S. Food and Drug Administration for Fesilty, a human fibrinogen product developed for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency. With...
Jacobio Pharma (1167.HK) announced that it has entered into a strategic agreement with AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) for its proprietary Pan-KRAS inhibitor, JAB-23E73. Under the terms of the deal, AstraZeneca will receive exclusive development and commercialization rights outside of China,...